CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York, NY.
Key points:
- CEO John Climaco will present at the conference
- Management will be available for one-on-one meetings with qualified investors
- A video webcast of the presentation will be available on-demand from September 9, 2024, at 7:00 AM ET
- The webcast will be accessible on the Company's website and archived for 90 days
This presentation offers an opportunity for CNS Pharmaceuticals to showcase its developments and engage with the investment community.
CNS Pharmaceuticals (NASDAQ:CNSP), un'azienda biofarmaceutica focalizzata nello sviluppo di nuovi trattamenti per i tumori del cervello e del sistema nervoso centrale, ha annunciato la sua partecipazione al 26° Annual Global Investment Conference di H.C. Wainwright. L'evento si svolgerà dal 9 all'11 settembre 2024 a New York, NY.
Punti chiave:
- Il CEO John Climaco presenterà alla conferenza
- Il management sarà disponibile per incontri one-to-one con investitori qualificati
- Una trasmissione video della presentazione sarà disponibile on-demand dal 9 settembre 2024, alle 7:00 AM ET
- La trasmissione sarà accessibile sul sito web dell'azienda e archiviata per 90 giorni
Questa presentazione offre a CNS Pharmaceuticals l'opportunità di mostrare i propri sviluppi e interagire con la comunità degli investitori.
CNS Pharmaceuticals (NASDAQ:CNSP), una empresa biofarmacéutica centrada en el desarrollo de nuevos tratamientos para los cánceres del cerebro y del sistema nervioso central, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversión H.C. Wainwright. El evento está programado para el 9 al 11 de septiembre de 2024 en Nueva York, NY.
Puntos clave:
- El CEO John Climaco presentará en la conferencia
- La dirección estará disponible para reuniones individuales con inversores calificados
- Una transmisión de video de la presentación estará disponible bajo demanda desde el 9 de septiembre de 2024, a las 7:00 AM ET
- La transmisión estará accesible en el sitio web de la empresa y se archivará durante 90 días
Esta presentación ofrece a CNS Pharmaceuticals la oportunidad de mostrar sus desarrollos e interactuar con la comunidad de inversores.
CNS Pharmaceuticals (NASDAQ:CNSP)는 뇌 및 중앙 신경계 암을 위한 새로운 치료법 개발에 초점을 맞춘 생물의약품 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕에서 진행됩니다.
주요 사항:
- CEO 존 클리마코가 컨퍼런스에서 발표할 예정입니다.
- 경영진은 자격을 갖춘 투자자와 개별 회의에 참석할 예정입니다.
- 발표의 비디오 웹캐스트는 2024년 9월 9일 오전 7시 ET부터 주문형으로 제공됩니다.
- 웹캐스트는 회사 웹사이트에서 접근 가능하며 90일간 기록될 것입니다.
이번 발표는 CNS Pharmaceuticals가 자사의 개발 사항을 선보이고 투자 커뮤니티와 소통할 수 있는 기회를 제공합니다.
CNS Pharmaceuticals (NASDAQ:CNSP), une entreprise biopharmaceutique axée sur le développement de nouveaux traitements pour les cancers du cerveau et du système nerveux central, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale d'Investissement H.C. Wainwright. L'événement est prévu du 9 au 11 septembre 2024 à New York, NY.
Points clés :
- Le PDG John Climaco présentera à la conférence
- La direction sera disponible pour des réunions individuelles avec des investisseurs qualifiés
- Un webinaire vidéo de la présentation sera disponible à la demande à partir du 9 septembre 2024, à 7h00 ET
- Le webinaire sera accessible sur le site de l'entreprise et archivé pendant 90 jours
Cette présentation offre à CNS Pharmaceuticals l'opportunité de mettre en avant ses développements et d'engager un dialogue avec la communauté des investisseurs.
CNS Pharmaceuticals (NASDAQ:CNSP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuer Behandlungen für Tumoren des Gehirns und des zentralen Nervensystems konzentriert, hat seine Teilnahme an der 26. Jahrestagung der Global Investment Conference von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet vom 9. bis 11. September 2024 in New York, NY, statt.
Wichtige Punkte:
- CEO John Climaco wird auf der Konferenz präsentieren
- Das Management steht für individuelle Meetings mit qualifizierten Investoren zur Verfügung
- Ein Video-Webcast der Präsentation wird ab dem 9. September 2024, um 7:00 Uhr ET, auf Abruf verfügbar sein
- Der Webcast wird auf der Unternehmenswebsite zugänglich sein und 90 Tage archiviert werden
Diese Präsentation bietet CNS Pharmaceuticals die Gelegenheit, seine Entwicklungen zu präsentieren und mit der Investmentgemeinschaft in Kontakt zu treten.
- None.
- None.
HOUSTON, TX / ACCESSWIRE / September 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 9, 2024, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company's website (cnspharma.com). The webcast replay will be archived for 90 days following the event.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When is CNS Pharmaceuticals (CNSP) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for CNS Pharmaceuticals (CNSP) at the investment conference?
Where can investors view the webcast of CNS Pharmaceuticals' (CNSP) presentation?
How long will the webcast of CNS Pharmaceuticals' (CNSP) presentation be available?
What is the focus of CNS Pharmaceuticals' (CNSP) research and development?
